00068-7/asset/2fbd481f-c6dd-4f43-bde1-3c6c1968b134/main.assets/gr1_lrg.jpg)
semaglutide nash phase 3 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled 2 trial Semaglutide shows liver benefits in
Description
Here is everything that you need to know.
According to Dr
Conclusions In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile
If youve heard about GLP-1 medications like Ozempic or Mounjaro, you probably know them as weight-loss drugs
Updated May 2026
Retatrutide is investigational and not FDA-approved
